Afternoon Symposium 1 - SGLT2-inhibitor and Cardiovascular Diseases: Where Are We Now?
Saturday, October 16th 2021 (13:00 – 14:05)
Will the advent of SGLT2-inhibitor help us improving the morbidity and mortality of patients with heart failure? If you'd like to know the answer, join us in this session to know how far have we been moving and where are we heading with the advent of SGLT2-inhibitor
13:00 - 13:15
When the Heart is Not Alone: Myth or Ally in Cardiovascular Comorbidities (Edrian Zulkarnaen, MD)
13:15 - 13:30
Expectation from Empagliflozin in Managing Cardiovascular Diseases: Learning from RCT and Real World Experience (Erwinanto, MD)